Company: TELO
Filing Date: 2025-09-04
Form Type: 8-K
Source: 0001641172-25-026527
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-09-04
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

On
August 28, 2025, Telomir Pharmaceuticals, Inc., completed its sale of a total of 1,550,000 shares of its common stock, no par
value, in block sales to institutional investors, at an average price of $1.87 per share (a premium to the prior day’s
close), through its at-the-market equity offering facility (the “ Offering”). Gross proceeds from the Offering totaled approximately $2.9
million, prior to deducting fees and expenses. The trades for the Offering were facilitated through Rodman & Renshaw, via the StockBlock
platform. The Offering did not include any warrants.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                         TELOMIR                                       
  Dated:                 By:                        /s/                
                         Name:                      Erez               
                         Title:                     Chief